Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 14/20 | 0.56 |
| ▸ | ATP4B | P51164 | 14/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.56 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | FASN | P49327 | 1/20 | 0.56 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.56 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.56 |
| ▸ | ATP1A1 | P05023 | 7/20 | 0.47 |
| ▸ | ATP1B1 | P05026 | 7/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30102856 | 1.00 | ATP4A (0.56) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| SCHEMBL15475057 | 0.93 | ATP4A (0.66) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| SCHEMBL23988512 | 0.91 | ATP4A (0.56) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| SCHEMBL23988520 | 0.90 | CYP2C9 (0.56) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| SCHEMBL23988474 | 0.89 | RUNX1 (0.51) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| SCHEMBL27634378 | 0.87 | ATP4A (0.54) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| SCHEMBL4563475 | 0.86 | ATP4A (0.54) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| SCHEMBL5616017 | 0.85 | ATP4A (0.53) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| SCHEMBL5616024 | 0.85 | ATP4A (0.53) | ATP4AATP4BCYP2C9KDM4ESLC22A2 | |
| SCHEMBL6359051 | 0.83 | ATP4A (0.58) | ATP4AATP4BCYP2C9KDM4ESLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111714639-A | Composition comprising histamine release-promoting substance and benzimidazole derivative | 黄泳华 | 2020-09-29 | — | — | CN | claimed |
| CN-111084886-A | Composition comprising fatty acid or derivative thereof and benzimidazole derivative | 黄泳华 | 2020-05-01 | — | — | CN | claimed |
| US-20250009728-A1 | BENZIMIDAZOLE DERIVATIVES COMPOSITIONS | HIKMA PHARMACEUTICALS USA INC. (US) | 2025-01-09 | — | — | US | disclosed |
| US-20230255949-A1 | BENZIMIDAZOLE DERIVATIVES COMPOSITIONS | HIKMA PHARMACEUTICALS USA INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230255949-A1 | BENZIMIDAZOLE DERIVATIVES COMPOSITIONS | HIKMA PHARMACEUTICALS USA INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230255949-A1 | BENZIMIDAZOLE DERIVATIVES COMPOSITIONS | HIKMA PHARMACEUTICALS USA INC. | 2023-08-17 | — | — | US | disclosed |
| CN-115444826-B | Preparation method of pantoprazole sodium for injection | 海南锦瑞制药有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-115444826-A | Preparation method of pantoprazole sodium for injection | 海南锦瑞制药有限公司 | 2022-12-09 | — | — | CN | disclosed |
| US-20220202796-A1 | CXCL10 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-06-30 | — | — | US | disclosed |
| CN-113125583-B | Method for detecting content of genotoxic impurities in pantoprazole sodium for injection | 成都百裕制药股份有限公司 | 2022-06-21 | — | — | CN | disclosed |
| US-20210338650-A1 | CXCL10 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| EP-1970374-A1 | Process for the production of substituted 2-(pyridin-2-ylmethylsulfinyl)-1H-benzimidazoles | Teva Pharmaceutical Industries Ltd. (IL) | 2008-09-17 | — | — | EP | disclosed |
| EP-1963305-A1 | AN IMPROVED PROCESS FOR PREPARING OF, IMPURITIES FREE, SUBSTITUTED 2-BENZIMIDAZOLESULFOXIDE COMPOUND | Pliva Hrvatska D.O.O. (HR) | 2008-09-03 | — | — | EP | disclosed |
| US-20080177076-A1 | Processes for preparing substantially pure pantoprazole magnesium | TEVA PHARMACEUTICALS USA, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080091024-A1 | Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles | TEVA PHARMACEUTICALS USA, INC. | 2008-04-17 | — | — | US | disclosed |
| WO-2007068925-A1 | AN IMPROVED PROCESS FOR PREPARING OF, IMPURITIES FREE, SUBSTITUTED 2-BENZIMIDAZOLESULFOXIDE COMPOUND | PLIVA HRVATSKA D.O.O. (HR) | 2007-06-21 | — | — | WO | disclosed |
| US-20060293363-A1 | Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2006-12-28 | — | — | US | disclosed |
| US-7129358-B2 | Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-10-31 | — | — | US | disclosed |
| US-20040138466-A1 | Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles | TEVA PHARMACEUTICALS USA, INC. | 2004-07-15 | — | — | US | disclosed |
| US-20030036554-A1 | Processes for the production fo substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles | TEVA PHARMACEUTICALS USA, INC. | 2003-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138466-A1 | Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles | PDXK, PIR, STS | ATP4A 3810/4885ATP4B 2821/4885CYP2C9 105/4885 |
| US-20230255949-A1 | BENZIMIDAZOLE DERIVATIVES COMPOSITIONS | TMBIM6, BCCIP, SBDS | ATP4A 2690/4885ATP4B 1937/4885CYP2C9 168/4885 |
| US-20250009728-A1 | BENZIMIDAZOLE DERIVATIVES COMPOSITIONS | TMBIM6, BCCIP, SBDS | ATP4A 2690/4885ATP4B 1937/4885CYP2C9 168/4885 |
| US-20080091024-A1 | Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles | PDXK, PIR, STS | ATP4A 3810/4885ATP4B 2821/4885CYP2C9 105/4885 |
| US-20220202796-A1 | CXCL10 Inhibitors | CXCL10, CCL5, CCL11 | ATP4A 4581/4885ATP4B 4629/4885CYP2C9 4152/4885 |
| US-20060293363-A1 | Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles | PDXK, PIR, STS | ATP4A 3810/4885ATP4B 2821/4885CYP2C9 105/4885 |
| US-20080177076-A1 | Processes for preparing substantially pure pantoprazole magnesium | PANK3, MLN, PANK1 | ATP4A 145/4885ATP4B 45/4885CYP2C9 65/4885 |
| US-20210338650-A1 | CXCL10 Inhibitors | CXCL10, CCL5, CCL11 | ATP4A 4581/4885ATP4B 4629/4885CYP2C9 4152/4885 |
| US-20030036554-A1 | Processes for the production fo substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles | CYP4F2, PIR, CYP4F3 | ATP4A 3388/4885ATP4B 1877/4885CYP2C9 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.